Phase 2 N=22 A Study of ATI-502 Topical Solution for the Treatment of Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Subjects withTreatment-Emergent Adverse Events (Safety and Tolerability) — 7 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=60 A ProspectiveTrial Comparing THUNDERBEAT to the Ligasure Energy Device During Laparoscopic Colon Surgery
Colon Cancer
Primary: Overall Time for Dissection of the Soft Tissues — 91; 77 minutes — p=0.214
N/A N=20 An Investigation of the Impact of Localized Topical Anesthesia of the Ocular Surface on End-of-day Contact Lens Discomfort
Visual Acuity
Primary: Subjective Comfort Scores — 79.25; 70.93; 61.00; 61.94 Units on a Scale
Phase 4 N=140 Feasibility of Vaginal Progesterone to Reduce HIV-Associated Preterm Birth
PreTerm Birth
Primary: Adequate Adherence to Study Product — 62; 63 Participants
Phase 2 N=9 A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization
Antibiotic Resistant Strain
Primary: Percentage of Participants With VRE Decolonization — 1; 1 Participants
N/A N=385 A Comparison of the Pacemaker Automatic Features in Reduction of Ventricular Pacing
Bradycardia
Primary: Number of Participants With Decreased Percent of Ventricular Pacing Compared to MVP Using Search AV+ — 1; 4 Participants — p=<0.0001
Phase 2 N=21 A Phase 2 Open-label Pilot Study Evaluating MYK-461 in Subjects With Symptomatic Hypertrophic Cardiomyopathy and Left Ventricular Outflow Tract Obstruction
Cardiomyopathy, Hypertrophic Obstructive · Left Ventricular Outflow Tract Obstruction
Primary: Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12 — -89.5; -25.0 mm Hg
Phase 3 N=201 Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
Papillomavirus Infections · Uterine Cervical Neoplasms · Vulvar Neoplasms
Primary: Seroconversion Percentages to HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58 at Month 7 — 100; 100; 100; 100.0 Percentage of Participants
Phase 2 N=133 Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Metastatic Colorectal Carcinoma · Recurrent Colorectal Carcinoma · Refractory Colorectal Carcinoma
Primary: Progression Free Survival (PFS) — 4.37; 3.32 months — p=0.051
Phase 2 N=11 Study of the Safety, Tolerability, and Pharmacokinetics of LHW090 in Patients With Moderately Impaired Renal Function
Chronic Kidney Disease (CKD)
Primary: Number of Patients With Reported Adverse Events Receiving Escalating Doses of LHW090 (Part 1) — 1; 0; 1; 2 Count of Participants
Early Phase 1 N=13 Probiotics for Quality of Life in Autism Spectrum Disorders
Autism Spectrum Disorders · Anxiety
Primary: Change in Gastrointestinal (GI) Module of the Pediatric Quality of Life Inventory (PedsQL) at From Baseline at Week 8 — 17.97; 7.98 Units on a scale
N/A N=22 Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis
Multiple Sclerosis
Primary: Fatigue — 21; 24 % decline
N/A N=196 Discharge Opioid Education to Decrease Opioid Use After Cesarean
Opioid Use
Primary: Opioid Use — 7.5; 10 hydrocodone tablets
N/A N=72 Transversus Abdominis Plane (TAP) Block for Postoperative Analgesia After Laparoscopic Colonic Resection
Colonic Cancer · Rectal Cancer · Colonic Diverticulum
Primary: Morphine Consumption in the First 48hours After the Operation — 47.3; 46.7 mg
Phase 3 N=48 EMERALD: Effects of Metformin on Cardiovascular Function in Adolescents With Type 1 Diabetes
Type 1 Diabetes
Primary: Change in Insulin Sensitivity — 12.2; -2.4 (mg/kg/min)/(insulin) — p=0.005